Literature DB >> 27027956

Severe Asthma: Have We Made Progress?

Audrey H Poon1, Qutayba Hamid1,2.   

Abstract

Tremendous efforts have been invested in research to (1) discover risk factors, biomarkers, and clinical characteristics; (2) understand the pathophysiology and treatment response variability in severe asthma; and (3) design new therapies. However, to combat severe asthma, many questions concerning the pathogenesis of severe asthma, including its natural history, genetic and environmental risk factors, and disease mechanisms, must be answered. In this article we highlight some of the major discoveries concerning the pathogenesis of severe asthma and its therapeutic development. We conclude that discoveries on numerous fronts of severe asthma, from disease heterogeneity, features of airway remodeling, cytokine mediators and signaling pathways underlying disease pathogenesis, disease mechanisms, potential biomarkers, to new therapeutic targets, demonstrate that progress has been made in understanding and developing more effective treatments for this difficult-to-treat disease.

Entities:  

Keywords:  airway remodeling; biomarkers; cytokines; severe asthma; steroid

Mesh:

Substances:

Year:  2016        PMID: 27027956     DOI: 10.1513/AnnalsATS.201508-514MG

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  6 in total

1.  Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.

Authors:  Nora Drick; Benjamin Seeliger; Tobias Welte; Jan Fuge; Hendrik Suhling
Journal:  BMC Pulm Med       Date:  2018-07-18       Impact factor: 3.317

2.  Upregulation of LncRNA Malat1 Induced Proliferation and Migration of Airway Smooth Muscle Cells via miR-150-eIF4E/Akt Signaling.

Authors:  Li Lin; Qinghai Li; Wanming Hao; Yu Zhang; Long Zhao; Wei Han
Journal:  Front Physiol       Date:  2019-10-22       Impact factor: 4.566

3.  Circular RNA ERBB2 Contributes to Proliferation and Migration of Airway Smooth Muscle Cells via miR-98-5p/IGF1R Signaling in Asthma.

Authors:  Jun-Qian Huang; Fang Wang; Long-Tao Wang; Yong-Mei Li; Jun-Li Lu; Jian-You Chen
Journal:  J Asthma Allergy       Date:  2021-09-29

4.  SREBP2 promotes the viability, proliferation, and migration and inhibits apoptosis in TGF-β1-induced airway smooth muscle cells by regulating TLR2/NF-κB/NFATc1/ABCA1 regulatory network.

Authors:  Yuebin Wang; Huike Yang; Xian Su; Anqiang Cao; Feng Chen; Peng Chen; Fangtao Yan; Huirong Hu
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

Review 5.  Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.

Authors:  Rosalia Emma; Jaymin B Morjaria; Virginia Fuochi; Riccardo Polosa; Massimo Caruso
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

6.  Adipose-Derived Mesenchymal Stem Cell-Derived Exosomal miR-301a-3p Regulates Airway Smooth Muscle Cells During Asthma by Targeting STAT3.

Authors:  Chen-Ye Feng; Shi-Yao Bai; Meng-Lu Li; Jie-Yu Zhao; Jia-Min Sun; Hui-Jing Bao; Yuan Ren; Xin-Ming Su
Journal:  J Asthma Allergy       Date:  2022-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.